Press enter to see results or esc to cancel.


OxThera is on a mission is to bring novel treatment options to rare kidney disease. The company holds proprietary rights to pharmaceutical preparations and their use for the treatment of hyperoxaluria. Oxabact has received orphan drug designations in the EU and the US for the treatment of Primary Hyperoxaluria (PH). Oxabact is an oral product …

Continue Reading